NCRI & Cancer52 research spend report published
A new report from the National Cancer Research Institute (NCRI) and Cancer52, ‘Research into less common cancers’ was published today, 4th November 2013. This shows, for the first time, the level and type of research investment in rare and less common cancers by members of Cancer52.
AMMF, as an active member of Cancer52, was one of the twenty-five charities who participated by submitting data for analysis for this report.
The report shows that research spend on less common cancers by members of Cancer52 totals c£6.3 million and accounts for 5.1 % of the total investment by NCRI Partners and Cancer52 members combined in these cancers.
The highest percentage of spend from within Cancer52 is on treatment research (47.01%), and the best funded cancer group is blood cancers (41.8%).
To read the full report, click here
and, for a summary of the key findings, click here
Chair of Cancer52, Allyson Kaye commented, “We very much welcome the investment made by the NCRI in analysing the investment in research by our members. Results demonstrate an investment of £6.3 million in 2012 and although spend by Cancer52 members is small compared to the bigger charities and government funders of cancer research, strategically placed investment can inform not only the rarer cancer but the bigger picture, too.”
“We look forward to receiving ongoing support from the NCRI in advising members on how best to make their research investments count on the wider platform.”
Eric Low, OBE, CEO of Myeloma UK and a member of the NCRI board said, ‘’Rare cancer charities make a significant financial contribution to cancer research but this often goes under the radar. This report, for the first time, quantifies the amount of research funded in hard cash. The next step will be to determine what the return on this investment has been in terms of patient benefit and how does this stack up pound for pound with investment in more common cancers. This work will take as a long way to determining what an optimal research funding model might look like in rare cancers.’’
Dr Karen Groot, Head of Programmes & Evaluation at the NCRI said “Our analysis of the spend on research by Cancer52 members highlights the important contribution these organisations make to research in less common cancers. The analysis also identified a number of examples of co-funding of research awards between Cancer52 members and NCRI Partners meaning Cancer52 member funds go further, increasing their potential to make a real difference to patients.”
The National Cancer Research Institute (NCRI) was established in 2001. It is a UK-wide partnership between the government, charity and industry which promotes cooperation in cancer research. For more information on the NCRI go to: http://www.ncri.org.uk
Cancer52 is an alliance of 70 organisations working together to address the inequalities that exist in policy, services and research for the rare and less common cancers, in order to improve the outcomes for patients with these challenging diseases.
Cancer52 members focus on a wide variety of rare and less common cancers with their activities ranging from patient support and advocacy to influencing policy and conducting research.
More information on Cancer52 can be found here: http://www.cancer52.org.uk/